GlassScriptPhysician profile
Kimberly Mcfee
NPI 1720624182
$2,553.28
in general payments reported to CMS, 2019-2025
34 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $240 · 2024: $808 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $263.25 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $254.47 | 2023-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $250.50 | 2024-2025 | |
| Daiichi Sankyo INC. | $177.41 | 2023-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $147.06 | 2024-2025 | Ninlaro, Iclusig |
| Deciphera Pharmaceuticals INC. | $109.10 | 2023-2025 | Qinlock, Tgct, Romvimza |
| Merck Sharp & Dohme LLC | $96.62 | 2024-2025 | Keytruda, Lynparza |
| Array Biopharma INC | $95.53 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Stemline Therapeutics INC. | $94.96 | 2024-2025 | Orserdu |
| Eisai INC. | $91.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $84.60 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Pfizer INC. | $84.28 | 2023-2025 | |
| Puma Biotechnology, INC. | $81.47 | 2025 | |
| Pharmaessentia USA Corporation | $80.40 | 2024-2025 | Besremi |
| Gilead Sciences, INC. | $67.19 | 2025 | Trodelvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $60.58 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $56.83 | 2025 | Danziten |
| Incyte Corporation | $55.06 | 2023-2025 | Monjuvi, Jakafi |
| Genzyme Corporation | $49.95 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.59 | 2025 | |
| Genmab U.S., INC. | $41.19 | 2024 | Tivdak |
| Lilly USA, LLC | $36.37 | 2025 | Jaypirca, Verzenio |
| Tactile Systems Technology INC | $32.63 | 2025 | Flexitouch Plus, Nimbl |
| Recordati_rare_diseases_inc. | $23.80 | 2025 | Sylvant |
| Beigene USA, INC. | $22.83 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $22.35 | 2023 | Zoladex |
| Syndax Pharmaceuticals, INC. | $21.81 | 2025 | Revuforj |
| Rigel Pharmaceuticals, INC. | $21.28 | 2024 | Tavalisse, Rezlidhia |
| Seagen INC. | $16.56 | 2023 | Padcev |
| Pharmacosmos Therapeutics INC. | $16.35 | 2025 | Monoferric |
| Blueprint Medicines Corporation | $15.75 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $13.87 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $13.49 | 2024 | |
| Cti Biopharma Corp. | $13.05 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Mcfee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.